A new trading day began on Friday, with Ovid Therapeutics Inc (NASDAQ: OVID) stock price down -7.63% from the previous day of trading, before settling in for the closing price of $0.38. OVID’s price has ranged from $0.37 to $3.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 284.57% over the last five years. Meanwhile, its annual earnings per share averaged -60.06%. With a float of $56.63 million, this company’s outstanding shares have now reached $71.01 million.
The firm has a total of 23 workers. Let’s measure their productivity. In terms of profitability, gross margin is 49.82%, operating margin of -10933.22%, and the pretax margin is -4669.96%.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 20.33%, while institutional ownership is 52.49%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -60.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.95% during the next five years compared to 24.72% growth over the previous five years of trading.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Here are Ovid Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 43.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.37, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Analysing the last 5-days average volume posted by the [Ovid Therapeutics Inc, OVID], we can find that recorded value of 0.44 million was better than the volume posted last year of 0.39 million. As of the previous 9 days, the stock’s Stochastic %D was 4.09%. Additionally, its Average True Range was 0.05.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 0.09%, which indicates a significant decrease from 0.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.82% in the past 14 days, which was higher than the 69.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5738, while its 200-day Moving Average is $0.9731. Now, the first resistance to watch is $0.3678. This is followed by the second major resistance level at $0.3856. The third major resistance level sits at $0.3950. If the price goes on to break the first support level at $0.3406, it is likely to go to the next support level at $0.3312. Now, if the price goes above the second support level, the third support stands at $0.3134.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
With a market capitalization of 24.88 million, the company has a total of 71,075K Shares Outstanding. Currently, annual sales are 570 K while annual income is -26,430 K. The company’s previous quarter sales were 80 K while its latest quarter income was -9,250 K.
